Home
About IBT
IBT History
Management
Board of Directors
Advisory Board
Sustainability Policy
Pipeline
IBP-9414
IBP-1016
IBP-1118
IBP-1122
Expanded Access Policy for Investigational Drugs
Families
Healthcare Professionals
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
Investors & Media Contact
Subscribe
Contact Us
Career
En
Sv
Home
About IBT
IBT History
Management
Board of Directors
Advisory Board
Sustainability Policy
Pipeline
IBP-9414
IBP-1016
IBP-1118
IBP-1122
Expanded Access Policy for Investigational Drugs
Families
Healthcare Professionals
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
Investors & Media Contact
Subscribe
Contact Us
Career
Press releases
Outcome of Infant Bacterial Therapeutics’ rights issue
February 2, 2018
To access the press release, please read the following disclaimer
here
.
Latest press releases
2025-11-13 07:30
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025
Regulatory
2025-10-20 10:35
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026
Regulatory
2025-10-13 14:35
Registration work for IBT's drug candidate IBP-9414 continues in the US and Europe
2025-09-10 09:38
IBT presented “Avoiding the severe consequences of NEC” at the NEC Society Symposium in Chicago
2025-08-20 08:00
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2025
Regulatory